Sandoz Group (OTCMKTS:SDZNY) and Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis

Vivos Therapeutics (NASDAQ:VVOS) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.

Risk & Volatility

Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Vivos Therapeutics and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Sandoz Group	N/A	N/A	N/A

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Sandoz Group shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Vivos Therapeutics and Sandoz Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Sandoz Group	0	1	0	3	3.50

Vivos Therapeutics presently has a consensus price target of $2.75, suggesting a potential upside of 310.45%. Given Vivos Therapeutics’ higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Sandoz Group.

Valuation and Earnings

This table compares Vivos Therapeutics and Sandoz Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.53	-$21.17 million	($2.14)	-0.31
Sandoz Group	$11.09 billion	3.31	$914.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than Vivos Therapeutics.

Summary

Sandoz Group beats Vivos Therapeutics on 8 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.